Menu
Back to Journals » Journal of Experimental Pharmacology » Volume 2
Recent advances in the treatment of multiple sclerosis
Authors Bennett JL, Miravalle A
Published 3 November 2010 Volume 2010:2 Pages 155—161
DOI https://doi.org/10.2147/JEP.S7822
Review by Single anonymous peer review
Peer reviewer comments 3
Jeffrey L Bennett, Augusto A Miravalle
University of Colorado, Aurora, CO, USA
Abstract: Multiple sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating, neurodegenerative disorder of the central nervous system. Despite the lack of an etiologic factor, it has been consistently demonstrated that the immune system plays a crucial role in the pathogenesis of MS. The traditional description of immunopathogenesis of MS suggests a preferential CD4+ TH1 cell activity causing tissue damage by the release of pro-inflammatory cytokines and subsequent demyelination and axonal loss. Recent evidence, however, suggests that other immune cells including TH17 cells, CD8+ effector T cells, CD4+ CD25+ regulatory T cells, and B cells may play a prominent role in MS immunopathology. A better understanding of the molecular and cellular components of the immunopathogenesis of MS is allowing the development of novel therapies.
Keywords: multiple sclerosis, immunopathology, oral medication, clinical trial
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.